Ascendis Pharma A (ASND) Convertible Debt (2022 - 2025)
Ascendis Pharma A (ASND) posted Convertible Debt of $499.8 million for Q4 2025, up 2.08% sequentially from $489.6 million in Q4 2024, and up 2.08% YoY from $489.6 million in Q4 2024.
Ascendis Pharma A (ASND) Convertible Debt (2022 - 2025) Analysis & Trends
Ascendis Pharma A has reported Convertible Debt for 3 years, with the latest figure at $499.8 million in Q4 2025.
- Quarterly Convertible Debt rose 2.08% year-over-year to $499.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $499.8 million (up 2.08% YoY) and the FY2025 annual result came in at $499.8 million, up 2.08% from the prior year.
- Convertible Debt improved to $499.8 million in Q4 2025 per ASND's latest filing, from $489.6 million in the prior quarter.
- Over five years, Convertible Debt peaked at $499.8 million in Q4 2025 and troughed at $407.3 million in Q4 2022.
- A 3-year average of $465.6 million and a median of $489.6 million in 2024 frame the typical range for Convertible Debt.
- The widest YoY moves for Convertible Debt: up 2.08% in 2025, down 2.08% in 2025.
- Over 3 years, Convertible Debt stood at $407.3 million in 2022, then gained by 20.22% to $489.6 million in 2024, then climbed by 2.08% to $499.8 million in 2025.
- According to Business Quant data, Convertible Debt over the past three periods registered $499.8 million, $489.6 million, and $407.3 million for Q4 2025, Q4 2024, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 499.83 Mn |
| Dec 31, 2024 | 489.64 Mn |
| Dec 31, 2022 | 407.27 Mn |